A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
for Multiple Myeloma
Drug: Belantamab mafodotin
Sites in Providence +29 more locations
Sponsor: GlaxoSmithKline
Sex: All·Age: 18+
Code: NCT06679101·Phase 3·Recruiting·Listed Nov 2024